Tag Archives: American Psychiatric Association

Electroconvulsive Therapy: Will The FDA Whitewash It?

For decades the FDA has allowed electroconvulsive therapy (ECT) to be used without requiring any proof of safety or efficacy. The machines and the treatment has been “grandfathered” into use rather than tested. A few years ago the FDA proposed to test the treatment but heavy pressure from the American Psychiatric Association caused the agency to reverse itself. ECT remains untested and widely used. Imagine that — the American Psychiatric Association doesn’t want an obviously dangerous treatment to be tested at all. It just wants psychiatrists left alone to inflict it upon hapless patients. The sad truth is that psychiatry has always promoted brain-damaging treatments, including lobotomy, electroshock and toxic chemical substances. In the 1970s I conducted an intensive international campaign to stop the resurgence of lobotomy and others forms of psychosurgery, and if my campaign had not been successful, lobotomy would have once again become widely accepted within contemporary psychiatry. Using media citations and other sources, that campaign and its success is documented in The Conscience of Psychiatry: The Reform Work of Peter R. Breggin, MD.

DSM: The Book of Woe—Inside the Battle to Define Mental Illness

Every so often Al Frances says something that seems to surprise even him. Just now, for instance, in the predawn darkness of his comfortable, rambling home in Carmel, California, he has broken off his exercise routine to declare that “there is no definition of a mental disorder. It’s bullshit. I mean, you just can’t define it.”

The insurgency against the DSM-5 (the APA has decided to shed the Roman numerals) has now spread far beyond just Allen Frances. Psychiatrists at the top of their specialties, clinicians at prominent hospitals, and even some contributors to the new edition have expressed deep reservations about it. Dissidents complain that the revision process is in disarray and that the preliminary results, made public for the first time in February 2010, are filled with potential clinical and public relations nightmares. Although most of the dissenters are squeamish about making their concerns public—especially because of a surprisingly restrictive nondisclosure agreement that all insiders were required to sign—they are becoming increasingly restive, and some are beginning to agree with Frances that public pressure may be the only way to derail a train that he fears will “take psychiatry off a cliff.”

Psychiatrist Asks, “Why Are People So Divided When It Comes To Children’s Mental Health?” We’ve Got the Answer…

Today’s Huffington Post features an article from psychiatrist Harold Koplewicz, frequently seen in the press leading the cheer for more psychiatric diagnosing and drugging of children. In today’s article, Koplewicz makes a plea to ‘Stop the Stigma’ which is preventing children from being diagnosed mentally ill. Pretty catchy slogan isn’t it? “Stop the Stigma.” It ought to be, it’s a brilliant marketing campaign, brought to you by Big Pharma, via the National Alliance on Mental Illness (NAMI), a group that masquerades as a “patient’s rights group for the mentally ill” but receives tens of millions in funding from Pharma.

Psychiatrists Dominate “Doctor-Dollars” Database Listing Big Pharma Payments

Dollar Value of Psychiatric Drugs Is Enormous— The preponderance of psychiatrists on the ProPublica list may reflect the proportion of prescription activity involving psychiatric drugs. In 2009, the dollar value of antipsychotic drugs came to $14.6 billion, topping all other therapeutic classes, according to research firm IMS Health. Antidepressants occupied the number 4 spot on the list, valued at $9.9 billion. IMS Health put the total US prescription market in 2009 at $300.3 billion.
Carol Bernstein, MD, president of the American Psychiatric Association, told Medscape Medical News that the thorny issue of pharmaceutical industry compensation went beyond her specialty.

Meet the Queen of “Preschool Depression” — and Her Drug Company Backers

The NYT Sunday magazine crowned Dr. Joan Luby as the queen of preschool depression this weekend, but failed to mention that Luby has taken cash from Johnson & Johnson (JNJ), Shire (SHPGY) and AstraZeneca (AZN) to study using atypical antipsychotics in young children. The article is significant because of the outsize role that the Times magazine plays in creating and naming new social trends.